Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
Wilkins D, Wählby Hamrén U, Chang Y, Clegg LE, Domachowske J, Englund JA, Muller WJ, Leach A, Kelly EJ, Villafana T. Wilkins D, et al. Among authors: muller wj. Pediatrics. 2024 Nov 1;154(5):e2024067174. doi: 10.1542/peds.2024-067174. Pediatrics. 2024. PMID: 39350745 Clinical Trial.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. Among authors: muller wj. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Simões EAF, et al. Among authors: muller wj. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634694 Free PMC article.
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
Dagan R, Hammitt LL, Seoane Nuñez B, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Chang Y, Currie A, Grenham A, Shroff M, Takas T, Mankad VS, Leach A, Villafana T. Dagan R, et al. Among authors: muller wj. J Pediatric Infect Dis Soc. 2024 Feb 26;13(2):144-147. doi: 10.1093/jpids/piad113. J Pediatric Infect Dis Soc. 2024. PMID: 38219024 Free PMC article. Clinical Trial.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Griffin MP, et al. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. N Engl J Med. 2020. PMID: 32726528 Clinical Trial.
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Domachowske J, et al. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. N Engl J Med. 2022. PMID: 35235733 Clinical Trial. No abstract available.
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
Segers H, Deville JG, Muller WJ, Manzanares A, Desai A, Neely M, Bordon V, Hanisch B, Lassaletta A, Fisher BT, Autmizguine J, Groll AH, Sinnar S, Croos-Dabrera R, Engelhardt M, Jones M, Kovanda LL, Arrieta AC. Segers H, et al. Among authors: muller wj. Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0048424. doi: 10.1128/aac.00484-24. Epub 2024 Nov 14. Antimicrob Agents Chemother. 2024. PMID: 39540734 Free PMC article. Clinical Trial.
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.
Bucayu RFT, Boge CLK, Yildirim I, Avilés-Robles M, Vora SB, Berman DM, Sharma TS, Sung L, Castagnola E, Palazzi DL, Danziger-Isakov L, Yin DE, Roilides E, Maron G, Tribble AC, Soler-Palacin P, López-Medina E, Romero J, Belani K, Arrieta AC, Carlesse F, Nolt D, Halasa N, Dulek D, Rajan S, Muller WJ, Ardura MI, Pong A, Gonzalez BE, Salvatore CM, Huppler AR, Aftandilian C, Abzug MJ, Chakrabarti A, Green M, Lutsar I, Knackstedt ED, Johnson SK, Steinbach WJ, Fisher BT, Wattier RL. Bucayu RFT, et al. Among authors: muller wj. J Pediatric Infect Dis Soc. 2024 Dec 30;13(12):633-638. doi: 10.1093/jpids/piae116. J Pediatric Infect Dis Soc. 2024. PMID: 39513400
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, Muller WJ. Gu Y, et al. Among authors: muller wj. Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article.
Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity.
Wen J, McCann S, Balevic SJ, Muller WJ, Hornik CD, Autmizguine J, Anderson SG, Payne EH, Turdalieva S, Gonzalez D; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Wen J, et al. Among authors: muller wj. J Clin Pharmacol. 2024 Dec;64(12):1491-1504. doi: 10.1002/jcph.6108. Epub 2024 Aug 9. J Clin Pharmacol. 2024. PMID: 39120865
386 results